NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) and Treace Medical Concepts (NASDAQ:TMCI – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Valuation & Earnings
This table compares NeuroOne Medical Technologies and Treace Medical Concepts”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroOne Medical Technologies | $12.10 million | 0.57 | -$3.61 million | ($0.95) | -0.80 |
| Treace Medical Concepts | $203.35 million | 1.63 | -$59.00 million | ($0.86) | -5.88 |
Risk and Volatility
NeuroOne Medical Technologies has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Treace Medical Concepts has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.
Insider & Institutional Ownership
16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Comparatively, 23.4% of Treace Medical Concepts shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and price targets for NeuroOne Medical Technologies and Treace Medical Concepts, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroOne Medical Technologies | 1 | 1 | 3 | 0 | 2.40 |
| Treace Medical Concepts | 1 | 1 | 3 | 0 | 2.40 |
NeuroOne Medical Technologies presently has a consensus target price of $7.33, suggesting a potential upside of 870.02%. Treace Medical Concepts has a consensus target price of $6.17, suggesting a potential upside of 21.87%. Given NeuroOne Medical Technologies’ higher possible upside, equities research analysts clearly believe NeuroOne Medical Technologies is more favorable than Treace Medical Concepts.
Profitability
This table compares NeuroOne Medical Technologies and Treace Medical Concepts’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeuroOne Medical Technologies | -71.50% | -128.12% | -86.34% |
| Treace Medical Concepts | -27.44% | -72.99% | -29.19% |
Summary
Treace Medical Concepts beats NeuroOne Medical Technologies on 9 of the 12 factors compared between the two stocks.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corp. (NASDAQ: NMTC) is a medical device company focused on developing thin-film electrode technology for neurological applications. Its products are designed to support the diagnosis, monitoring and treatment of disorders affecting the brain and nervous system. The company’s product portfolio includes the Evo cortical and stereoelectroencephalography (sEEG) electrode systems, which are used by clinicians to record electrical activity in the brain and help evaluate patients with conditions such as epilepsy.
About Treace Medical Concepts
Treace Medical Concepts, Inc. develops and markets medical devices for foot and ankle surgery, with a focus on treatments for bunions and related deformities. Its products are designed for use by surgeons in correcting and stabilizing bones and joints in the foot. The company’s offerings include the Lapiplasty 3D Bunion Correction System, which uses specialized instruments and fixation implants to support correction of bunion deformities in three dimensions. Treace also sells systems and implants for other foot and ankle procedures, including treatments for deformities involving the midfoot and big toe.
Receive News & Ratings for NeuroOne Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
